Burlington-based LabCorp has launched the first testing method to simultaneously detect coronavirus, influenza A and B, and respiratory syncytial virus (RSV).
The single-panel test, which detects multiple types of infections, can help doctors diagnose patients and make decisions about treatment options.
The test is available to patients through doctors, hospitals and other authorized healthcare providers nationwide.
LabCorp has also submitted an application to the U.S. Food and Drug Administration to offer the combined test through its Pixel by LabCorp™ at-home test collection kit, which would offer added convenience and accessibility.